Mark De Rosch's most recent trade in CervoMed Inc was a trade of 30,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CervoMed Inc | Mark De Rosch | EVP, RA and GA and PgM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2026 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Mark De Rosch | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Mark De Rosch | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 42,250 | 58,635 | - | 0 | Common Stock | |
| Aura Biosciences Inc | Mark De Rosch | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 12.46 per share. | 31 Oct 2022 | 1,115 | 16,385 | - | 12.5 | 13,890 | Common Stock |